PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis

NYSEARCA:PLX • US74365A3095

3.14 USD
+0.08 (+2.61%)
At close: Feb 23, 2026
3.1714 USD
+0.03 (+1%)
After Hours: 2/23/2026, 8:09:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PLX. PLX was compared to 521 industry peers in the Biotechnology industry. PLX has only an average score on both its financial health and profitability. PLX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year PLX was profitable.
  • PLX had a negative operating cash flow in the past year.
  • In multiple years PLX reported negative net income over the last 5 years.
  • In the past 5 years PLX reported 4 times negative operating cash flow.
PLX Yearly Net Income VS EBIT VS OCF VS FCFPLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

  • With an excellent Return On Assets value of 8.00%, PLX belongs to the best of the industry, outperforming 92.90% of the companies in the same industry.
  • The Return On Equity of PLX (12.57%) is better than 93.47% of its industry peers.
  • The Return On Invested Capital of PLX (12.68%) is better than 95.20% of its industry peers.
Industry RankSector Rank
ROA 8%
ROE 12.57%
ROIC 12.68%
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLX Yearly ROA, ROE, ROICPLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • Looking at the Profit Margin, with a value of 10.13%, PLX belongs to the top of the industry, outperforming 90.98% of the companies in the same industry.
  • PLX has a better Operating Margin (13.28%) than 92.32% of its industry peers.
  • PLX's Gross Margin of 57.53% is fine compared to the rest of the industry. PLX outperforms 78.12% of its industry peers.
  • PLX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 13.28%
PM (TTM) 10.13%
GM 57.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
PLX Yearly Profit, Operating, Gross MarginsPLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PLX is creating some value.
  • PLX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PLX has been increased compared to 5 years ago.
  • PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLX Yearly Shares OutstandingPLX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLX Yearly Total Debt VS Total AssetsPLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of 0.12, we must say that PLX is in the distress zone and has some risk of bankruptcy.
  • With a decent Altman-Z score value of 0.12, PLX is doing good in the industry, outperforming 61.04% of the companies in the same industry.
  • PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.12
ROIC/WACC1.43
WACC8.87%
PLX Yearly LT Debt VS Equity VS FCFPLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

2.3 Liquidity

  • PLX has a Current Ratio of 2.72. This indicates that PLX is financially healthy and has no problem in meeting its short term obligations.
  • PLX has a worse Current ratio (2.72) than 68.91% of its industry peers.
  • PLX has a Quick Ratio of 1.84. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.84, PLX is not doing good in the industry: 76.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 1.84
PLX Yearly Current Assets VS Current LiabilitesPLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 153.85% over the past year.
  • Looking at the last year, PLX shows a very negative growth in Revenue. The Revenue has decreased by -18.47% in the last year.
  • PLX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.48% yearly.
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%

3.2 Future

  • Based on estimates for the next years, PLX will show a very strong growth in Earnings Per Share. The EPS will grow by 85.63% on average per year.
  • The Revenue is expected to grow by 10.46% on average over the next years. This is quite good.
EPS Next Y-15.83%
EPS Next 2Y142.73%
EPS Next 3Y85.63%
EPS Next 5YN/A
Revenue Next Year7.48%
Revenue Next 2Y15.38%
Revenue Next 3Y10.46%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PLX Yearly Revenue VS EstimatesPLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
PLX Yearly EPS VS EstimatesPLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • PLX is valuated quite expensively with a Price/Earnings ratio of 44.86.
  • Based on the Price/Earnings ratio, PLX is valued cheaper than 91.36% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.64. PLX is valued rather expensively when compared to this.
  • PLX is valuated rather expensively with a Price/Forward Earnings ratio of 17.77.
  • Based on the Price/Forward Earnings ratio, PLX is valued cheaply inside the industry as 94.43% of the companies are valued more expensively.
  • PLX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.75.
Industry RankSector Rank
PE 44.86
Fwd PE 17.77
PLX Price Earnings VS Forward Price EarningsPLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • PLX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PLX is cheaper than 94.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.55
PLX Per share dataPLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

  • PLX's earnings are expected to grow with 85.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y142.73%
EPS Next 3Y85.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PLX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (2/23/2026, 8:09:29 PM)

After market: 3.1714 +0.03 (+1%)

3.14

+0.08 (+2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-12
Inst Owners17.52%
Inst Owner Change6.7%
Ins Owners3.54%
Ins Owner Change0.8%
Market Cap252.52M
Revenue(TTM)53.40M
Net Income(TTM)6.28M
Analysts80
Price Target11.22 (257.32%)
Short Float %5.7%
Short Ratio3.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.51%
Min EPS beat(2)-265.02%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-90.87%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)2
Avg EPS beat(8)-112.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.6%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)14.45%
Revenue beat(4)2
Avg Revenue beat(4)-8.41%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)5
Avg Revenue beat(8)3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12%
PT rev (3m)-21.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-80.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-4.05%
Revenue NY rev (3m)-4.25%
Valuation
Industry RankSector Rank
PE 44.86
Fwd PE 17.77
P/S 4.08
P/FCF N/A
P/OCF N/A
P/B 5.06
P/tB 5.06
EV/EBITDA 20.55
EPS(TTM)0.07
EY2.23%
EPS(NY)0.18
Fwd EY5.63%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.77
BVpS0.62
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.99
Profitability
Industry RankSector Rank
ROA 8%
ROE 12.57%
ROCE 15.12%
ROIC 12.68%
ROICexc 32.84%
ROICexgc 32.84%
OM 13.28%
PM (TTM) 10.13%
GM 57.53%
FCFM N/A
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 91.23%
Cap/Sales 2.02%
Interest Coverage 10.74
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 1.84
Altman-Z 0.12
F-Score6
WACC8.87%
ROIC/WACC1.43
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-15.83%
EPS Next 2Y142.73%
EPS Next 3Y85.63%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
Revenue Next Year7.48%
Revenue Next 2Y15.38%
Revenue Next 3Y10.46%
Revenue Next 5YN/A
EBIT growth 1Y155.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.67%
OCF growth 3YN/A
OCF growth 5YN/A

PROTALIX BIOTHERAPEUTICS INC / PLX FAQ

What is the ChartMill fundamental rating of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PLX.


Can you provide the valuation status for PROTALIX BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to PROTALIX BIOTHERAPEUTICS INC (PLX). This can be considered as Fairly Valued.


What is the profitability of PLX stock?

PROTALIX BIOTHERAPEUTICS INC (PLX) has a profitability rating of 5 / 10.


How financially healthy is PROTALIX BIOTHERAPEUTICS INC?

The financial health rating of PROTALIX BIOTHERAPEUTICS INC (PLX) is 6 / 10.